Reverse remodeling and recovery from cachexia in rats with aldosteronism

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 303, Issue 4, 2012, Pages

  Cheema, Yaser ^a   Zhao, Wenyuan ^a   Zhao, Tieqiang ^a   Khan, M Usman ^a   Green, Kelly D ^a   Ahokas, Robert A ^a   Gerling, Ivan C ^a   Bhattacharya, Syamal K ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Cardiomyocyte necrosis; Intracellular calcium overloading; Mitochondria; Oxidative stress

Indexed keywords

8 ISOPROSTANE; ALDOSTERONE; CALCIUM ION; HYDROGEN PEROXIDE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CATABOLISM; CELL HETEROGENEITY; CELL STRUCTURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CONVALESCENCE; GENE EXPRESSION; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HYPERALDOSTERONISM; MALE; MICROSCOPY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; RAT; SCAR FORMATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WEIGHT GAIN;

ANIMALS; CACHEXIA; CALCIUM; CARDIOMEGALY; DINOPROST; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HEART FAILURE; HYDROGEN PEROXIDE; HYPERALDOSTERONISM; MALE; MITOCHONDRIA, HEART; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MUSCLE, SKELETAL; MUSCULAR ATROPHY; MYOCARDIUM; MYOCYTES, CARDIAC; NECROSIS; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; TIME FACTORS; VENTRICULAR REMODELING;

EID: 84865107204     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00192.2012     Document Type: Article

References (44)

1. Bartling B, Milting H, Schumann H, Darmer D, Arusoglu L, Koerner MM, El-Banayosy A, Koerfer R, Holtz J, Zerkowski HR. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation 100: II216-II223, 1999.
2. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89: 151-163, 1994.
3. Brooks WW, Shen S, Conrad CH, Goldstein RH, Deng LL, Bing OH. Transcriptional changes associated with recovery from heart failure in the SHR. J Mol Cell Cardiol 49: 390-401, 2010.
4. Bruckner BA, Razeghi P, Stetson S, Thompson L, Lafuente J, Entman M, Loebe M, Noon G, Taegtmeyer H, Frazier OH, Youker K. Degree of cardiac fibrosis and hypertrophy at time of implantation predicts myocardial improvement during left ventricular assist device support. J Heart Lung Transplant 23: 36-42, 2004.
5. Burch GE, Walsh JJ, Black WC. Value of prolonged bed rest in management of cardiomegaly. JAMA 183: 81-87, 1963.
6. Cheema Y, Sherrod JN, Shahbaz AU, Zhao W, Zhao T, Ahokas RA, Sun Y, Bhattacharya SK, Gerling IC, Weber KT. Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol. J Cardiovasc Pharmacol 58: 80-86, 2011.
7. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation 111: 871-878, 2005.
8. Chhokar VS, Sun Y, Bhattacharya SK, Ahokas RA, Myers LK, Xing Z, Smith RA, Gerling IC, Weber KT. Loss of bone minerals and strength in rats with aldosteronism. Am J Physiol Heart Circ Physiol 287: H2023-H2026, 2004.
9. De Giusti VC, Nolly MB, Yeves AM, Caldiz CI, Villa-Abrille MC, Chiappe de Cingolani GE, Ennis IL, Cingolani HE, Aiello EA. Aldosterone stimulates the cardiac Na /H exchanger via transactivation of the epidermal growth factor receptor. Hypertension 58: 912-919, 2011.
10. Dhalla NS, Saini-Chohan HK, Rodriguez-Leyva D, Elimban V, Dent MR, Tappia PS. Subcellular remodelling may induce cardiac dysfunction in congestive heart failure. Cardiovasc Res 81: 429-438, 2009.
11. Gandhi MS, Deshmukh PA, Kamalov G, Zhao T, Zhao W, Whaley JT, Tichy JR, Bhattacharya SK, Ahokas RA, Sun Y, Gerling IC, Weber KT. Causes and consequences of zinc dyshomeostasis in rats with chronic aldosteronism. J Cardiovasc Pharmacol 52: 245-252, 2008.
12. Gerling IC, Sun Y, Ahokas RA, Wodi LA, Bhattacharya SK, Warrington KJ, Postlethwaite AE, Weber KT. Aldosteronism: an immunostimulatory state precedes the proinflammatory/fibrogenic cardiac phenotype. Am J Physiol Heart Circ Physiol 285: H813-H821, 2003.
13. González A, Ravassa S, Beaumont J, López B, Díez J. New targets to treat the structural remodeling of the myocardium. J Am Coll Cardiol 58: 1833-1843, 2011.
14. Ibrahim M, Terracciano CM, Yacoub MH. Bridge to recovery: what remains to be discovered? Cardiol Clin 29: 531-547, 2011.
15. Jalil JE, Janicki JS, Pick R, Abrahams C, Weber KT. Fibrosis-induced reduction of endomyocardium in the rat after isoproterenol treatment. Circ Res 65: 258-264, 1989.
16. Kamalov G, Ahokas RA, Zhao W, Johnson PL, Shahbaz AU, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism. Am J Physiol Heart Circ Physiol 298: H385-H394, 2010.
17. Kamalov G, Deshmukh PA, Baburyan NY, Gandhi MS, Johnson PL, Ahokas RA, Bhattacharya SK, Sun Y, Gerling IC, Weber KT. Coupled calcium and zinc dyshomeostasis and oxidative stress in cardiac myocytes and mitochondria of rats with chronic aldosteronism. J Cardiovasc Pharmacol 53: 414-423, 2009.
18. Kass DA, Baughman KL, Pak PH, Cho PW, Levin HR, Gardner TJ, Halperin HR, Tsitlik JE, Acker MA. Reverse remodeling from cardiomyoplasty in human heart failure. External constraint versus active assist. Circulation 91: 2314-2318, 1995.
19. Khaper N, Bryan S, Dhingra S, Singal R, Bajaj A, Pathak CM, Singal PK. Targeting the vicious inflammation-oxidative stress cycle for the management of heart failure. Antioxid Redox Signal 13: 1033-1049, 2010.
20. Klotz S, Burkhoff D, Garrelds IM, Boomsma F, Danser AH. The impact of left ventricular assist device-induced left ventricular unloading on the myocardial renin-angiotensin-aldosterone system: therapeutic consequences? Eur Heart J 30: 805-812, 2009.
21. Kramer F, Sandner P, Klein M, Krahn T. Plasma concentrations of matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1 and osteopontin reflect severity of heart failure in DOCA-salt hypertensive rat. Biomarkers 13: 270-281, 2008.
22. Lalani R, Bhasin S, Byhower F, Tarnuzzer R, Grant M, Shen R, Asa S, Ezzat S, Gonzalez-Cadavid NF. Myostatin and insulin-like growth factor-I and-II expression in the muscle of rats exposed to the microgravity environment of the NeuroLab space shuttle flight. J Endocrinol 167: 417-428, 2000.
23. Lenchik NI, Desiderio DM, Gerling IC. Two-dimensional gel electrophoresis characterization of the mouse leukocyte proteome, using a trireagent for protein extraction. Proteomics 5: 2202-2209, 2005.
24. Lisy O, Redfield MM, Jovanovic S, Jougasaki M, Jovanovic A, Leskinen H, Terzic A, Burnett JC Jr. Mechanical unloading versus neurohumoral stimulation on myocardial structure and endocrine function in vivo. Circulation 102: 338-343, 2000.
25. Margulies KB. Reversal mechanisms of left ventricular remodeling: lessons from left ventricular assist device experiments. J Card Fail 8: S500-505, 2002.
26. Masiero E, Sandri M. Autophagy inhibition induces atrophy and myopathy in adult skeletal muscles. Autophagy 6: 307-309, 2010.
27. Okamoto H. Osteopontin and cardiovascular system. Mol Cell Biochem 300: 1-7, 2007.
28. Razeghi P, Mukhopadhyay M, Myers TJ, Williams JN, Moravec CS, Frazier OH, Taegtmeyer H. Myocardial tumor necrosis factor-alpha expression does not correlate with clinical indices of heart failure in patients on left ventricular assist device support. Ann Thorac Surg 72: 2044-2050, 2001.
29. Razeghi P, Sharma S, Ying J, Li YP, Stepkowski S, Reid MB, Taegtmeyer H. Atrophic remodeling of the heart in vivo simultaneously activates pathways of protein synthesis and degradation. Circulation 108: 2536-2541, 2003.
30. Regula KM, Ens K, Kirshenbaum LA. Inducible expression of BNIP3 provokes mitochondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ Res 91: 226-231, 2002.
31. Rossi E, Perazzoli F, Negro A, Sani C, Davoli S, Dotti C, Casoli MC, Regolisti G. Acute effects of intravenous sodium chloride load on calcium metabolism and on parathyroid function in patients with primary aldosteronism compared with subjects with essential hypertension. Am J Hypertens 11: 8-13, 1998.
32. Ruff RL, Weissmann J. Endocrine myopathies. Neurol Clin 6: 575-592, 1988.
33. Sam F, Xie Z, Ooi H, Kerstetter DL, Colucci WS, Singh M, Singh K. Mice lacking osteopontin exhibit increased left ventricular dilation and reduced fibrosis after aldosterone infusion. Am J Hypertens 17: 188-193, 2004.
34. Shahbaz AU, Kamalov G, Zhao W, Zhao T, Johnson PL, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC, Weber KT. Mitochondriatargeted cardioprotection in aldosteronism. J Cardiovasc Pharmacol 57: 37-43, 2011.
35. Sukhanov S, Semprun-Prieto L, Yoshida T, Michael Tabony A, Higashi Y, Galvez S, Delafontaine P. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci 342: 143-147, 2011.
36. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosteroneinduced inflammation in the rat heart. Role of oxidative stress. Am J Pathol 161: 1773-1781, 2002.
37. Torre-Amione G, Stetson SJ, Youker KA, Durand JB, Radovancevic B, Delgado RM, Frazier OH, Entman ML, Noon GP. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: a potential mechanism for cardiac recovery. Circulation 100: 1189-1193, 1999.
38. Weber KT. From inflammation to fibrosis: a stiff stretch of highway. Hypertension 43: 716-719, 2004.
39. Weglicki WB, Chmielinska JJ, Kramer JH, Mak IT. Cardiovascular and intestinal responses to oxidative and nitrosative stress during prolonged magnesium deficiency. Am J Med Sci 342: 125-128, 2011.
40. Weglicki WB, Mak IT, Stafford RE, Dickens BF, Cassidy MM, Phillips TM. Neurogenic peptides and the cardiomyopathy of magnesium-deficiency: effects of substance P-receptor inhibition. Mol Cell Biochem 130: 103-109, 1994.
41. Wohlschlaeger J, Schmitz KJ, Schmid C, Schmid KW, Keul P, Takeda A, Weis S, Levkau B, Baba HA. Reverse remodeling following insertion of left ventricular assist devices (LVAD): a review of the morphological and molecular changes. Cardiovasc Res 68: 376-386, 2005.
42. Wu J, Lenchik NI, Gerling IC. Approaches to reduce false positives and false negatives in the analysis of microarray data: applications in type 1 diabetes research. BMC Genomics 9, Suppl 2: S12, 2008.
43. Yogi A, Callera GE, O'Connor SE, He Y, Correa JW, Tostes RC, Mazur A, Touyz RM. Dysregulation of renal transient receptor potential melastatin 6/7 but not paracellin-1 in aldosterone-induced hypertension and kidney damage in a model of hereditary hypomagnesemia. J Hypertens 29: 1400-1410, 2011.
44. Zweier JL, Chen CA, Talukder MA. Cardiac resynchronization therapy and reverse molecular remodeling: importance of mitochondrial redox signaling. Circ Res 109: 716-719, 2011.